SEARCH

SEARCH BY CITATION

References

  • Adams, J.M. & Cory, S. (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene, 26, 13241337.
  • Borner, C. (2003) The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Molecular Immunology, 39, 615647.
  • Bosch, F., Jares, P., Campo, E., Lopez-Guillermo, A., Piris, M.A., Villamor, N., Tassies, D., Jaffe, E.S., Montserrat, E., Rozman, C. & Cardesa, A. (1994) PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood, 84, 27262732.
  • Brooks, C. & Dong, Z. (2007) Regulation of mitochondrial morphological dynamics during apoptosis by Bcl-2 family proteins: a key in Bak? Cell Cycle, 6, 30433047.
  • Byrd, J.C., Kitada, S., Flinn, I.W., Aron, J.L., Pearson, M., Lucas, D. & Reed, J.C. (2002) The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood, 99, 10381043.
  • Campo, E., Raffeld, M. & Jaffe, E.S. (1999) Mantle-cell lymphoma. Seminars in Hematology, 36, 115127.
  • Camps, J., Salaverria, I., Garcia, M.J., Prat, E., Bea, S., Pole, J.C., Hernandez, L., Del Rey, J., Cigudosa, J.C., Bernues, M., Caldas, C., Colomer, D., Miro, R. & Campo, E. (2006) Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. [see comment]. Leukemia Research, 30, 923934.
  • D’Arena, G., Musto, P., Cascavilla, N., Dell’Olio, M., Di Renzo, N. & Carotenuto, M. (2000) Quantitative flow cytometry for the differential diagnosis of leukemic B-cell chronic lymphoproliferative disorders. American Journal of Hematology, 64, 275281.
  • Danial, N.N. & Korsmeyer, S.J. (2004) Cell death: critical control points. Cell, 116, 205219.
  • Decker, T., Oelsner, M., Kreitman, R.J., Salvatore, G., Wang, Q.C., Pastan, I., Peschel, C. & Licht, T. (2004) Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood, 103, 27182726.
  • Van Delft, M.F., Wei, A.H., Mason, K.D., Vandenberg, C.J., Chen, L., Czabotar, P.E., Willis, S.N., Scott, C.L., Day, C.L., Cory, S., Adams, J.M., Roberts, A.W. & Huang, D.C. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.[see comment]. Cancer Cell, 10, 389399.
  • Dreyling, M., Weigert, O., Hiddemann, W. & European, M.C.L.N. (2008) Current treatment standards and future strategies in mantle cell lymphoma. Annals of Oncology, 19(Suppl. 4), iv4144.
  • Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H.P., Repp, R., Wandt, H., Pott, C., Seymour, J.F., Metzner, B., Hanel, A., Lehmann, T., Hartmann, F., Einsele, H., Hiddemann, W. & German Low Grade Lymphoma Study, G (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 108, 40034008.
  • Freedman, A.S., Neuberg, D., Gribben, J.G., Mauch, P., Soiffer, R.J., Fisher, D.C., Anderson, K.C., Andersen, N., Schlossman, R., Kroon, M., Ritz, J., Aster, J. & Nadler, L.M. (1998) High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. Journal of Clinical Oncology, 16, 1318.
  • Hanahan, D. & Weinberg, R.A. (2000) The hallmarks of cancer. Cell, 100, 5770.
  • Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B., Gatter, K.C., Grogan, T.M., Isaacson, P.G., Knowles, D.M., Mason, D.Y., Muller-Hermelink, H.K., Pileri, S.A., Piris, M.A., Ralfkiaer, E. & Warnke, R.A. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 13611392.
  • Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 38353849.
  • Howard, O.M., Gribben, J.G., Neuberg, D.S., Grossbard, M., Poor, C., Janicek, M.J. & Shipp, M.A. (2002) Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. Journal of Clinical Oncology, 20, 12881294.
  • Hussain, S.R., Cheney, C.M., Johnson, A.J., Lin, T.S., Grever, M.R., Caligiuri, M.A., Lucas, D.M. & Byrd, J.C. (2007) Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clinical Cancer Research, 13, 21442150.
  • Jadayel, D.M., Lukas, J., Nacheva, E., Bartkova, J., Stranks, G., De Schouwer, P.J., Lens, D., Bartek, J., Dyer, M.J., Kruger, A.R. & Catovsky, D. (1997) Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin’s lymphomas. Functional studies in a cell line (Granta 519). Leukemia, 11, 6472.
  • Jares, P., Colomer, D. & Campo, E. (2007) Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nature Reviews. Cancer, 7, 750762.
  • Jeon, H.J., Kim, C.W., Yoshino, T. & Akagi, T. (1998) Establishment and characterization of a mantle cell lymphoma cell line. British Journal of Haematology, 102, 13231326.
  • Keppler-Hafkemeyer, A., Brinkmann, U. & Pastan, I. (1998) Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry, 37, 1693416942.
  • Keppler-Hafkemeyer, A., Kreitman, R.J. & Pastan, I. (2000) Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies. International Journal of Cancer, 87, 8694.
  • Kreitman, R.J. & Pastan, I. (1995) Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochemical Journal, 307, (Pt 1), 2937.
  • Kreitman, R.J. & Pastan, I. (1998) Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Research, 58, 968975.
  • Kreitman, R.J., Wang, Q.C., FitzGerald, D.J. & Pastan, I. (1999) Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. International Journal of Cancer, 81, 148155.
  • Kreitman, R.J., Wilson, W.H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D.J. & Pastan, I. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. New England Journal of Medicine, 345, 241247.
  • Kreitman, R.J., Squires, D.R., Stetler-Stevenson, M., Noel, P., FitzGerald, D.J., Wilson, W.H. & Pastan, I. (2005) Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. Journal of Clinical Oncology, 23, 67196729.
  • Leonard, J.P., Schattner, E.J. & Coleman, M. (2001) Biology and management of mantle cell lymphoma. Current Opinion in Oncology, 13, 342347.
  • Mansfield, E., Amlot, P., Pastan, I. & FitzGerald, D.J. (1997) Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood, 90, 20202026.
  • Melo, J.V., Brito-Babapulle, V., Foroni, L., Robinson, D.S., Luzzatto, L. & Catovsky, D. (1986) Two new cell lines from B-prolymphocytic leukaemia: characterization by morphology, immunological markers, karyotype and Ig gene rearrangement. International Journal of Cancer, 38, 531538.
  • Menendez, P., Vargas, A., Bueno, C., Barrena, S., Almeida, J., De Santiago, M., Lopez, A., Roa, S., San Miguel, J.F. & Orfao, A. (2004) Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation. Leukemia, 18, 491498.
  • Mizushima, S. & Nagata, S. (1990) pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Research, 18, 5322.
  • Mounier, N., Briere, J., Gisselbrecht, C., Emile, J.F., Lederlin, P., Sebban, C., Berger, F., Bosly, A., Morel, P., Tilly, H., Bouabdallah, R., Reyes, F., Gaulard, P. & Coiffier, B. (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood, 101, 42794284.
  • Mozola, M.A., Wilson, R.B., Jordan, E.M., Draper, R.K. & Clowes, R.C. (1984) Cloning and expression of a gene segment encoding the enzymatic moiety of Pseudomonas aeruginosa exotoxin A. Journal of Bacteriology, 159, 683687.
  • Ogata, M., Fryling, C.M., Pastan, I. & FitzGerald, D.J. (1992) Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. Journal of Biological Chemistry, 267, 2539625401.
  • Pastan, I. & Kreitman, R.J. (2002) Immunotoxins in cancer therapy. Current Opinion in Investigational Drugs, 3, 10891091.
  • Pastan, I., Hassan, R., Fitzgerald, D.J. & Kreitman, R.J. (2006) Immunotoxin therapy of cancer. Nature Reviews. Cancer, 6, 559565.
  • Popat, U., Hosing, C., Saliba, R.M., Anderlini, P., Van Besien, K., Przepiorka, D., Khouri, I.F., Gajewski, J., Claxton, D., Giralt, S., Rodriguez, M., Romaguera, J., Hagemeister, F., Ha, C., Cox, J., Cabanillas, F., Andersson, B.S. & Champlin, R.E. (2004) Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin’s lymphoma. Bone Marrow Transplantation, 33, 10151023.
  • Pro, B., Leber, B., Smith, M., Fayad, L., Romaguera, J., Hagemeister, F., Rodriguez, A., McLaughlin, P., Samaniego, F., Zwiebel, J., Lopez, A., Kwak, L. & Younes, A. (2008) Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. British Journal of Haematology, 143, 355360.
  • Saltman, D.L., Cachia, P.G., Dewar, A.E., Ross, F.M., Krajewski, A.S., Ludlam, C. & Steel, C.M. (1988) Characterization of a new non-Hodgkin’s lymphoma cell line (NCEB-1) with a chromosomal (11:14) translocation [t(11:14)(q13;q32)]. Blood, 72, 20262030.
  • Siegall, C.B., Chaudhary, V.K., FitzGerald, D.J. & Pastan, I. (1989) Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. Journal of Biological Chemistry, 264, 1425614261.
  • Tucker, C.A., Kapanen, A.I., Chikh, G., Hoffman, B.G., Kyle, A.H., Wilson, I.M., Masin, D., Gascoyne, R.D., Bally, M. & Klasa, R.J. (2008) Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels. Molecular Cancer Therapeutics, 7, 749758.
  • Walker, J.A. & Smith, K.G. (2008) Dependence of surface monoclonal antibody binding on dynamic changes in FcgammaRIIb expression. [erratum appears in Immunology. 2008 Jul;124(3):417]. Immunology, 124, 412418.
  • Wilson, W.H. (2006) Drug resistance in diffuse large B-cell lymphoma. [see comment]. Seminars in Hematology, 43, 230239.